Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

PROTID Randomised Controlled Trial of Preventive Treatment of Latent Tuberculosis Infection in Patients with Diabetes Mellitus

Coordinator
Stichting Radboud Universitair Medisch Centrum, Netherlands
Runs
1 July 2024 to 31 December 2026
Status
Running
EU funding
€2.3m
Total cost
€2.3m
Partners
7 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101145612

What the project is doing

In the project's own words, from its summary on CORDIS.

Diabetes Mellitus (DM) contributes to an estimated 11.3% of adult deaths worldwide. Approximately 1 in 10 adults globally are estimated to have DM and the prevalence will rise significantly over the coming decades, especially in sub-Saharan Africa. People with DM have a three-fold increased risk of developing TB, and two-fold higher risk of dying from TB or experiencing treatment failure or recurrent disease, further threatening global TB control.

As such, the growing burden of DM alongside the continuing TB epidemic have huge health and socio- economic impact. PROTID performs the first randomized controlled trial (RCT) globally to evaluate efficacy, safety, cost-utility and population impact of preventive treatment of TB preventive therapy for people with DM. It also examines gaps in diagnosis and management of DM and DM-TB in Uganda and Tanzania. Our results will guide global policy on TB prevention and management in people with DM, and this can have large socio-economic impact.

In Africa, this is highly relevant given the double burden of DM and TB. In Europe, our results will be highly relevant for migrants and people living in eastern Europe, as both groups have a high burden of DM, latent tuberculosis infection (LTBI) and TB disease. PROTID’s results so far, and other advancements in the field, have already set clear research priorities beyond PROTID. PROTID is very well-positioned to take these forward, with strengthened leadership and research capacity in PROTID’s African partners embedded in a global research network, and its accumulated data on the largest and most-well characterized longitudinal cohort on DM and TB globally.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Radboud Universitair Medisch CentrumNijmegenNetherlandsCoordinator
University of OtagoDunedinNew ZealandParticipant
National Institute for Medical ResearchDar Es SalaamTZParticipant
The Good Samaritan FoundationMoshiTZParticipant
Makerere UniversityKampalaUGParticipant
King's College LondonLondonUnited KingdomAssociatedpartner
St George's Hospital Medical SchoolLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI